SG11201401193XA - TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS - Google Patents

TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Info

Publication number
SG11201401193XA
SG11201401193XA SG11201401193XA SG11201401193XA SG11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA SG 11201401193X A SG11201401193X A SG 11201401193XA
Authority
SG
Singapore
Prior art keywords
obesity
treatment
related disorders
potassium channels
pharmacological targeting
Prior art date
Application number
SG11201401193XA
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn-Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of SG11201401193XA publication Critical patent/SG11201401193XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG11201401193XA 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS SG11201401193XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
SG11201401193XA true SG11201401193XA (en) 2014-05-29

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401193XA SG11201401193XA (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Country Status (16)

Country Link
US (2) US20150072940A1 (en)
EP (1) EP2763702A4 (en)
JP (1) JP2014531469A (en)
KR (1) KR20140108518A (en)
CN (1) CN103987408A (en)
AU (1) AU2012318736A1 (en)
BR (1) BR112014008065A2 (en)
CA (1) CA2850357A1 (en)
HK (1) HK1201048A1 (en)
IL (1) IL231873A0 (en)
IN (1) IN2014CN03333A (en)
MX (1) MX2014004029A (en)
RU (1) RU2014117558A (en)
SG (1) SG11201401193XA (en)
TW (1) TW201321403A (en)
WO (1) WO2013052507A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294124B2 (en) * 2004-10-07 2012-02-23 Bachem Biosciences, Inc. Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
TWI535455B (en) 2011-06-06 2016-06-01 奇尼塔一有限責任公司 Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013052507A1 (en) 2011-10-03 2013-04-11 The Regents Of The University Of California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS
JP7211704B2 (en) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス A tablet containing a GLP-1 agonist and an enteric coating
TWI698438B (en) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Kv1.3 inhibitors and their medical application
TWI701249B (en) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Kv1.3 inhibitors and their medical application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
WO1999013895A1 (en) * 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
JP3207823B2 (en) 1999-04-28 2001-09-10 リノール油脂株式会社 Brown fat enhancer containing conjugated linoleic acid as active ingredient
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
AU2005294124B2 (en) * 2004-10-07 2012-02-23 Bachem Biosciences, Inc. Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
BRPI0616995A2 (en) * 2005-08-17 2011-07-05 Solvay Pharm Gmbh pharmaceutical composition, and use of kv1.3 potassium channel inhibitor in drug preparation
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2013052507A1 (en) 2011-10-03 2013-04-11 The Regents Of The University Of California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Also Published As

Publication number Publication date
KR20140108518A (en) 2014-09-11
CA2850357A1 (en) 2013-04-11
RU2014117558A (en) 2015-11-10
US20150072940A1 (en) 2015-03-12
EP2763702A1 (en) 2014-08-13
EP2763702A4 (en) 2015-04-15
MX2014004029A (en) 2014-08-01
CN103987408A (en) 2014-08-13
IN2014CN03333A (en) 2015-07-03
US20170095530A1 (en) 2017-04-06
BR112014008065A2 (en) 2019-09-24
IL231873A0 (en) 2014-05-28
TW201321403A (en) 2013-06-01
JP2014531469A (en) 2014-11-27
WO2013052507A1 (en) 2013-04-11
AU2012318736A1 (en) 2014-05-22
HK1201048A1 (en) 2015-08-21
US9878006B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
HUS2000032I1 (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases.
EP2670478A4 (en) Devices, systems and methods for the targeted treatment of movement disorders
HK1201048A1 (en) Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels kv13
EP2575816A4 (en) Combination therapy for skin disorders
PL2704704T3 (en) Probiotic bacteria for the topical treatment of skin disorders
ZA201305897B (en) Combination therapy
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
ZA201401952B (en) Immunocytokine combination therapy
ZA201400120B (en) Combination therapy
EP2890370A4 (en) Agents useful for treating obesity, diabetes and related disorders
IL232710B (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
EP2720708A4 (en) Targeting the neuromuscular junction for treatment
IL225896A0 (en) Treatment of mecp2-associated disorders
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2675275A4 (en) Compositions and methods for the treatment of obesity and related disorders
EP2701744A4 (en) Combination therapy
ZA201308176B (en) Therapeutic treatment
IL214123A0 (en) Massage appatus fo rthe shower
EP2726505A4 (en) Therapeutic targeting of ficolin-3
GB0912587D0 (en) Therapeutic uses for plants of the capsicum genus
GB201118065D0 (en) Treatment of movement disorders
AU2012900788A0 (en) Combination treatment for rheumatic disorders
AU335490S (en) Physiotherapy band
AU335277S (en) Physiotherapy band
GB201101183D0 (en) Treatment of neurodegenerative disorders